Mumbai: From a rural e-swasthya initiative to an international real-estate fund, the Piramal Group is planned to launch several initiatives across its different businesses, the Chairman, Mr Ajay Piramal, said launching the Group''s new corporate identity. The re-branding exercise coincides with the 20th anniversary of the Group''s flagship company, Nicholas Piramal India Ltd, now renamed Piramal Healthcare Ltd (PHL). The company''s pharmaceutical business will keep on to grow along the domestic and customs manufacturing segments. The customs manufacturing segment, where it manufactures products for overseas customers, will now be called pharma solutions. The company is open to divesting a small percentage of equity in its recently demerged research entity.
The research entity will get listed in June, and is being approached by strategic investors and private equity (PE) companies interested in the research entity. Independent valuations estimate the research entity to be valued between $480 million and $540 million. The Group is also planned to unveil its second, larger international fund via its Indiareit Fund Advisors Pvt Ltd.
The research entity will get listed in June, and is being approached by strategic investors and private equity (PE) companies interested in the research entity. Independent valuations estimate the research entity to be valued between $480 million and $540 million. The Group is also planned to unveil its second, larger international fund via its Indiareit Fund Advisors Pvt Ltd.
